Exploring the adoption of less restricted criteria for respiratory syncytial virus prophylaxis in late preterm infants: insights from a retrospective analysis

Exploring the adoption of less restricted criteria for respiratory syncytial virus prophylaxis in late preterm infants: insights from a retrospective analysis

BackgroundPreterm infants born between 33 and 35 weeks of gestational age (wGA) have been considered a “major underserved population” and ineligible to receive palivizumab (PLV), the only drug authorized to date for respiratory syncytial virus (RSV) prophylaxis, by current international guidelines....

Full description

Bibliographic Details
Main Authors: Vito Mondì, Piermichele Paolillo, Manuela Bedetta, Natalia Lucangeli, Simonetta Picone
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-06-01
Series:Frontiers in Pediatrics
Subjects:
respiratory syncytial virus
bronchiolitis
prophylaxis
late preterm
risk factor
Online Access:https://www.frontiersin.org/articles/10.3389/fped.2023.1154518/full

Internet

https://www.frontiersin.org/articles/10.3389/fped.2023.1154518/full

Similar Items